HER2-specific chimeric antigen receptor–modified virus-specific T cells for progressive glioblastoma: A phase 1 dose-escalation trial

JAMA Oncology

Volumn 3, Issue 8, 2017, Pages 1094-1101

  Ahmed, Nabil ^a   Brawley, Vita ^a   Hegde, Meenakshi ^a   Bielamowicz, Kevin ^a,b   Kalra, Mamta ^a,c   Landi, Daniel ^a   Robertson, Catherine ^a   Gray, Tara L ^a   Diouf, Oumar ^a,d   Wakefield, Amanda ^a   Ghazi, Alexia ^a,e   Gerken, Claudia ^a   Yi, Zhongzhen ^a   Ashoori, Aidin ^a,f   Wu, Meng Fen ^a   Liu, Hao ^a   Rooney, Cliona ^a   Dotti, Gianpietro ^a,g   Gee, Adrian ^a   Su, Jack ^a   Kew, Yvonne ^h   Baskin, David ^h   Zhang, Yi Jonathan ^h   New, Pamela ^h   Grilley, Bambi ^a   Stojakovic, Milica ^a   Hicks, John ^a   Powell, Suzanne Z ^h   Brenner, Malcolm K ^a   Heslop, Helen E ^a   Grossman, Robert ^h   Wels, Winfried S ⁱ   Gottschalk, Stephen ^a   more..

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c IMMATICS BIOTECHNOLOGIES GMBH   (Germany)

^d Cell Medica Ltd   (United Kingdom)

^e BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^f Department of Medicine   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h HOUSTON METHODIST HOSPITAL   (United States)

ⁱ INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CD28 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADENOVIRIDAE; ADOLESCENT; ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATELECTASIS; BLOOD ANALYSIS; BLOOD TOXICITY; BONE PAIN; BRADYCARDIA; BRAIN EDEMA; CANCER SURVIVAL; CELL THERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CHIMERIC ANTIGEN RECEPTOR EPIDERMAL GROWTH FACTOR RECEPTOR 2 VIRUS SPECIFIC T CELL THERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; DIARRHEA; DNA MODIFICATION; EAR DISEASE; EAR PARALYSIS; EDEMA; EPSTEIN BARR VIRUS; FATIGUE; FEMALE; FOLLOW UP; FRACTURE; GAIT DISORDER; GLIOBLASTOMA; HEADACHE; HUMAN; HYDROCEPHALUS; HYPERBILIRUBINEMIA; HYPERKALEMIA; HYPERNATREMIA; HYPONATREMIA; IN VIVO STUDY; LYMPHOCYTOPENIA; MALE; MEMORY DISORDER; MYALGIA; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PATIENT SAFETY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SEIZURE; SIGNAL TRANSDUCTION; SOMNOLENCE; THROMBOCYTOPENIA; TREMOR; URINARY TRACT INFECTION; VOMITING; WEAKNESS; BRAIN NEOPLASMS; CHILD; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; T LYMPHOCYTE; TRANSPLANTATION; TREATMENT OUTCOME;

ADENOVIRIDAE; ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CHILD; CYTOMEGALOVIRUS; FEMALE; GLIOBLASTOMA; HERPESVIRUS 4, HUMAN; HUMANS; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 85021976256     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2017.0184     Document Type: Article

References (35)

1. Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;314(23):2535-2543.
2. Cohen KJ, Pollack IF, Zhou T, et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children’s Oncology Group. Neuro Oncol. 2011;13(3):317-323.
3. Pollack IF, Jakacki RI, Butterfield LH, et al. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol. 2014;32 (19):2050-2058.
4. Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28(31):4722-4729.
5. Mitchell DA, Batich KA, Gunn MD, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015;519 (7543):366-369.
6. Suryadevara CM, Verla T, Sanchez-Perez L, et al. Immunotherapy for malignant glioma. Surg Neurol Int. 2015;6(suppl 1):S68-S77.
7. Brown CE, Alizadeh D, Starr R, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375(26):2561-2569.
8. Brown CE, Badie B, Barish ME, et al. Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res. 2015;21(18):4062-4072.
9. Johnson LA, Scholler J, Ohkuri T, et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med. 2015;7(275): 275ra22.
10. Chow KK, Naik S, Kakarla S, et al. T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther. 2013;21(3):629-637.
11. Ahmed N, Salsman VS, Kew Y, et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res. 2010;16(2): 474-485.
12. Sampson JH, Choi BD, Sanchez-Perez L, et al. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res. 2014;20(4):972-984.
13. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4): 843-851.
14. Ahmed N, Brawley VS, Hegde M, et al. Human epidermal growth factor receptor 2 (HER2)–specific chimeric antigen receptor–modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol. 2015;33(15):1688-1696.
15. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14(11):1264-1270.
16. Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12(10):1160-1166.
17. Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013;121(26):5113-5123.
18. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194.
19. National Cancer Institute, National Institutes of Health. CTCAE files. https://evs.nci.nih.gov/ftp1/CTCAE/About.html. Updated May 17, 2010. Accessed March 19, 2017.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92(3):205-216.
21. Hong JJ, Rosenberg SA, Dudley ME, et al. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res. 2010;16(19):4892-4898.
22. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-1517.
23. Schuessler A, Smith C, Beagley L, et al. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res. 2014;74(13):3466-3476.
24. Louis CU, Straathof K, Bollard CM, et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010;33(9):983-990.
25. Louis CU, Straathof K, Bollard CM, et al. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 2009;113(11):2442-2450.
26. Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5): 925-935.
27. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517-528.
28. Cooper LJ, Al-Kadhimi Z, Serrano LM, et al. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood. 2005;105(4):1622-1631.
29. Okada H, Weller M, Huang R, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015;16(15):e534-e542.
30. Franceschi E, Ermani M, Bartolini S, et al. Post progression survival in glioblastoma: where are we? J Neurooncol. 2015;121(2):399-404.
31. Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15(9):943-953.
32. Preusser M, Lim M, Hafler DA, Reardon DA, Sampson JH. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol. 2015;11(9):504-514.
33. Roy LO, Poirier MB, Fortin D. Transforming growth factor-beta and its implication in the malignancy of gliomas. Target Oncol. 2015;10(1):1-14.
34. Hegde M, Mukherjee M, Grada Z, et al. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. J Clin Invest. 2016;126(8): 3036-3052.
35. Hegde M, Corder A, Chow KK, et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther. 2013; 21(11):2087-2101.